Parkinson’s: Beyond the hidden barriers

The definitive guide to accelerating adoption of
new treatments in Parkinson’s

Click REGISTER INTEREST to stay updated on the guide's availability or request a free summary

This guide uses leading behavioural science approaches to transform how you plan and deliver communications for Parkinson’s.
Parkinson’s remains one of the greatest challenges in medicine. Current therapies focus on symptoms. New treatments have failed to meet expectations. These all lead to complex barriers to adoption.
Yet with 139 treatments in clinical trials, it’s crucial to communicate effectively more than ever to ensure any new treatment is adopted.

This groundbreaking guide will equip you to understand and address barriers to changing prescribing behaviours in Parkinson’s. Beyond identifying challenges, it proposes potential solutions using the unique, validated Healthcare Behaviour Insights Tool (H-BIT) methodology developed by Alpharmaxim and Aston University, UK.

Taking the H-BIT approach, you can radically change the way you plan and execute communications, get the uptake you want and reach patients in need of new options for Parkinson’s treatment.

How will this guide support your work in Parkinson’s?

By harnessing the insights of this guide, your communications have a greater chance of driving behaviour change and adoption of product, whether you work in Marketing, Medical Affairs, Strategic Planning, Market Access or Clinical Development.

Build launch plans to better differentiate your product
Understand market changes and be ahead of the curve
Address key issues in the right ways using scientifically validated tools
Appreciate and address clinician behaviours in the field
Develop greater understanding of how to positively change behaviour
Deliver measurable campaign effectiveness that demonstrates real ROI

What you’ll get from the guide

The H-BIT guide will provide valuable detail on the drivers of behaviour that determine physicians’ decision-making, specifically focusing on their capability, opportunity and motivation to change their current behaviour.

Our research shows that when we consider an approach for Parkinson’s, directing communications solely at neurologists will not be effective. Though they are critical in prescribing, much of the support we can give to neurologists may be addressed through changing the prescribing environment – looking again at the provision of clear treatment guidelines and patient journeys, as well as better facilitating the role of non-specialist HCPs.

If these issues are addressed through the behavioural interventions covered in the guide, it’s likely that neurologists will have increased capability and motivation to change prescribing patterns, and so the adoption of new therapies may be accelerated.

Many neurologists are slow to adopt new treatments for PD, and the introduction of new disease-modifying treatments will likely slow adoption further. Our guide highlights several behavioural components that are responsible. Addressing these underlying challenges with focused intervention will be critical to driving adoption of new treatments.

The guide is in the final stages of development and will validate and address the hidden barriers to adoption of new treatments. We believe this research will substantially improve the impact of your communications in Parkinson’s.

To be among the first to receive updates on the availability of the research, please provide your details below.

About Alpharmaxim

Alpharmaxim was founded in 2001, helping cross-functional biopharma teams communicate effectively with clinicians about new medicines or alternative treatment regimes and their potential to improve the patient experience. With a significant focus on pre- and peri-launch work in speciality healthcare, Alpharmaxim has always had a strong awareness of the need to change behaviours and beliefs, and introduced the Belief Continuum^® in 2007, with copyright granted in 2016. Alpharmaxim has consistently invested in behavioural science. We have established ARM BeSci Consulting – a specialist team within Alpharmaxim.

Working with our academic partners, we have developed a proprietary model that practically evaluates and analyses behaviours and barriers to change. This model also identifies the proven and most effective behaviour change techniques to overcome these barriers. By adopting a behavioural science approach to communications planning, clients can expect targeted communications that achieve greater success, enabling more clarity and ensuring the right patients get the right medicine at the right time.

The guide is for individual use and is Copyright Alpharmaxim Limited. All data in the guide is owned by Alpharmaxim. Please contact us about multiple-copy discounts.

1. Cure Parkinson’s. Parkinson’s drug therapies in the clinical trial pipeline: 2023 update. https://cureparkinsons.org.uk/2023/06/parkinsons-clinical-trial-pipeline-2023/. Accessed 27 June 2024